Basic Information
RNALocate ID: | RLID-D:11000640 |
RNA Symbol: | hsa-miR-150-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-150-3p |
RNA ID: | miRBase:MIMAT0004610 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
Tissue/Cell Line: | Colon cancer cell line (LIM1863)|Mesenchymal stem cells |
Database: | EVmiRNA |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11003787 | Exosome | Saliva | 19627513 |
RLID:11003788 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11003789 | Exosome | Plasma | 23663360 |
RLID:11003790 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11001515 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-150-3p | Medulloblastoma | MNDR-E-MI-16510 |
MNDR | hsa-miR-150-3p | B cell lymphoma of malt type | MNDR-E-MI-16511 |
MNDR | hsa-miR-150-3p | Lymphoma | MNDR-E-MI-16512 |
MNDR | hsa-miR-150-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-16513 |
MNDR | hsa-miR-150-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-16514 |
MNDR | hsa-miR-150-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-16515 |
MNDR | hsa-miR-150-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-16516 |
MNDR | hsa-miR-150-3p | Her2-receptor positive breast cancer | MNDR-E-MI-16517 |
MNDR | hsa-miR-150-3p | Breast cancer luminal | MNDR-E-MI-16518 |
MNDR | hsa-miR-150-3p | Prostate cancer | MNDR-E-MI-16519 |
MNDR | hsa-miR-150-3p | Gastric cancer | MNDR-E-MI-16520 |
MNDR | hsa-miR-150-3p | Intracranial aneurysm | MNDR-E-MI-16521 |
MNDR | hsa-miR-150-3p | Lung cancer | MNDR-E-MI-16522 |
MNDR | hsa-miR-150-3p | Biliary atresia | MNDR-E-MI-16523 |
MNDR | hsa-miR-150-3p | Parkinson disease | MNDR-E-MI-16524 |
MNDR | hsa-miR-150-3p | Basal-like breast cancer | MNDR-E-MI-16525 |
MNDR | hsa-miR-150-3p | Pancreatic cancer | MNDR-E-MI-16526 |
MNDR | hsa-miR-150-3p | Rectum adenocarcinoma | MNDR-E-MI-16527 |
MNDR | hsa-miR-150-3p | Nephroblastoma | MNDR-E-MI-16528 |
MNDR | hsa-miR-150-3p | Colon cancer | MNDR-E-MI-16529 |
MNDR | hsa-miR-150-3p | Colon adenocarcinoma | MNDR-E-MI-16530 |
MNDR | hsa-miR-150-3p | Familial ovarian cancer | MNDR-E-MI-16531 |
MNDR | hsa-miR-150-3p | Carcinoma ductal breast | MNDR-E-MI-16532 |
MNDR | hsa-miR-150-3p | Glioblastoma | MNDR-E-MI-16533 |
MNDR | hsa-miR-150-3p | Astrocytoma | MNDR-E-MI-16534 |
MNDR | hsa-miR-150-3p | Chordoma | MNDR-E-MI-16535 |
MNDR | hsa-miR-150-3p | Osteosarcoma | MNDR-E-MI-16536 |
MNDR | hsa-miR-150-3p | Infarction middle cerebral artery | MNDR-E-MI-16537 |
MNDR | hsa-miR-150-3p | Liver cancer | MNDR-E-MI-16538 |
MNDR | hsa-miR-150-3p | Gastric adenocarcinoma | MNDR-E-MI-16539 |
MNDR | hsa-miR-150-3p | Lung squamous cell carcinoma | MNDR-E-MI-16540 |
MNDR | hsa-miR-150-3p | Lung adenocarcinoma | MNDR-E-MI-16541 |
MNDR | hsa-miR-150-3p | Thyroid carcinoma | MNDR-E-MI-16542 |
MNDR | hsa-miR-150-3p | Bladder urothelial carcinoma | MNDR-E-MI-16543 |
MNDR | hsa-miR-150-3p | Pancreatic adenocarcinoma | MNDR-E-MI-16544 |
MNDR | hsa-miR-150-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-16545 |
MNDR | hsa-miR-150-3p | Renal clear cell carcinoma | MNDR-E-MI-16546 |
MNDR | hsa-miR-150-3p | Biliary tract cancer | MNDR-E-MI-16547 |
MNDR | hsa-miR-150-3p | Cholangiocarcinoma | MNDR-E-MI-16548 |
MNDR | hsa-miR-150-3p | Esophageal cancer | MNDR-E-MI-16549 |
MNDR | hsa-miR-150-3p | Lung small cell carcinoma | MNDR-E-MI-16550 |
MNDR | hsa-miR-150-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-16551 |
MNDR | hsa-miR-150-3p | Testicular germ cell cancer | MNDR-E-MI-16552 |
MNDR | hsa-miR-150-3p | Myocardial infarction | MNDR-E-MI-16553 |
MNDR | hsa-miR-150-3p | Breast invasive carcinoma | MNDR-E-MI-16554 |
MNDR | hsa-miR-150-3p | Hepatocellular carcinoma | MNDR-E-MI-16555 |
MNDR | hsa-miR-150-3p | Embryonal cancer | MNDR-E-MI-16556 |
MNDR | hsa-miR-150-3p | Familiar ovarian carcinoma | MNDR-E-MI-16557 |
MNDR | hsa-miR-150-3p | B-cell lymphoma | MNDR-E-MI-16558 |
MNDR | hsa-miR-150-3p | Hodgkin lymphoma | MNDR-E-MI-16559 |
MNDR | hsa-miR-150-3p | Skin cutaneous melanoma | MNDR-E-MI-16560 |
MNDR | hsa-miR-150-3p | Skin melanoma | MNDR-E-MI-16561 |
MNDR | hsa-miR-150-3p | Colorectal cancer | MNDR-E-MI-16562 |
MNDR | hsa-miR-150-3p | Nasopharynx carcinoma | MNDR-E-MI-16563 |
MNDR | hsa-miR-150-3p | Multiple myeloma | MNDR-E-MI-16564 |
MNDR | hsa-miR-150-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-16565 |
MNDR | hsa-miR-150-3p | Nasopharyngeal cancer | MNDR-E-MI-16566 |
MNDR | hsa-miR-150-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-16567 |
MNDR | hsa-miR-150-3p | Breast cancer her3+ negative | MNDR-E-MI-16568 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CCNT1 | Homo sapiens | RR00296614 |
TOP